Breathomix
Breathomix, founded in 2018, develops BreathBase, a point-of-care breath-analysis platform intended to support clinical diagnosis and patient management. The company targets healthcare providers and patients in diagnostic settings.
- Company typePrivate
- Founded2018
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Breathomix does
Breathomix is a privately held, for-profit company founded in 2018 that is developing BreathBase, a solution intended to bring breath-based diagnostics to the point of care. According to its own short positioning statement, the company aims to transform how patients are diagnosed and managed, implying a clinical-decision-support or screening use case that would be deployed in clinics, hospitals, or other care settings rather than as a consumer wellness product.
The core offering appears to be a hardware-software system that analyzes exhaled breath for disease-relevant biomarkers, with the explicit design goal of point-of-care usability — a category that historically relies on electronic-nose sensors, spectrometry, or gas chromatography combined with machine-learning classifiers trained on volatile organic compound (VOC) profiles. The company has not disclosed product SKUs, technical specifications, regulatory pathway (e.g., CE-IVD, FDA 510(k)), or clinical validation data in the available source material, and its public website content was inaccessible at the time of data collection, so deeper technical claims cannot be verified.
No revenue model, pricing structure, customer segments, geographic footprint, funding history, management team, or partnership information is present in the supplied data. As a result, the business model mechanics — how Breathomix monetizes (device sales, consumables, SaaS, licensing, or research collaborations) — cannot be determined from the available evidence, and any assessment of commercial traction is constrained accordingly.
Breathomix firmographics
Firmographics- Name
- Breathomix
- Website
- https://breathomix.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 11–50 employees
- Short description
- Breathomix, founded in 2018, develops BreathBase, a point-of-care breath-analysis platform intended to support clinical diagnosis and patient management. The company targets healthcare providers and patients in diagnostic settings.
- Ownership category
- akta.pro rank
Breathomix industry classification
Industry- Product category
- Point-of-Care Diagnostics
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Pulmonary Function Testing (PFT) & Spirometry Equipment (HLAHAGAH)
- akta.pro secondary industries
- Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC), Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)
Keywords
Where Breathomix is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Breathomix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Breathomix product offering
Product offeringCore offering
Breathomix develops and delivers the BreathBase solution for point-of-care patient diagnosis and management. The solution is intended to bring breath-based diagnostic capability directly to the point-of-care rather than relying on centralized laboratory testing, enabling clinicians to assess and manage patients at the bedside or near-patient setting.
Differentiator
Problem solved
Functional benefit
Products and services
- BreathBase Point-of-care breath analysis solution intended to transform the way patients are diagnosed and managed, bringing breath-based diagnostic capability to the point-of-care for healthcare providers.
Companies that use Breathomix
Customer profileIdeal customer profiles1 record
Breathomix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Breathomix partnerships and signals
Strategic signalRecent moves1 record
Breathomix competitors and assessment
Company assessmentDirect peers
- Owlstone Medical: Owlstone Medical develops breath biopsy diagnostics for disease detection including lung cancer and respiratory conditions, making it the most direct comparable to Breathomix's BreathBase platform.
- CAIRE Diagnostics (formerly Spirosure): CAIRE Diagnostics markets the Fenom Pro point-of-care FeNO breath analyzer for asthma management, directly competing with Breathomix in point-of-care respiratory diagnostics.
- Bedfont Scientific: Bedfont manufactures breath analysis devices such as the NObreath FeNO monitor and Smokerlyzer, offering overlapping point-of-care respiratory diagnostic products comparable to BreathBase.
- ndd Medical Technologies: ndd produces ultrasonic pulmonary function testing and FeNO devices used in respiratory diagnostics, a closely related device category to Breathomix's offering.
- Vitalograph: Vitalograph manufactures spirometry, respiratory screening, and FeNO devices for clinical and occupational health use, overlapping with Breathomix's point-of-care respiratory focus.
- MGC Diagnostics (now part of CAIRE): MGC Diagnostics (now operating under CAIRE) provides pulmonary function and cardiopulmonary diagnostic equipment, a comparable device-based respiratory diagnostics portfolio.
Broad incumbents
- Bosch Healthcare Solutions (Vivatmo): Bosch Healthcare Solutions markets Vivatmo, a FeNO-based home and clinical breath analyzer for asthma, making it a large established player in the same breath diagnostics category.
Emerging players
- AerNos: AerNos develops nano-gas-sensor technology for detecting disease biomarkers in exhaled breath, addressing the same emerging breath-diagnostics market as Breathomix.
- PulmOne Advanced Medical Devices: PulmOne develops miniaturized point-of-care pulmonary function testing systems, offering a direct point-of-care respiratory diagnostic alternative to Breathomix's approach.
Regional players
- Respiratory Motion (ExSpiron): Respiratory Motion develops non-invasive minute ventilation monitoring (ExSpiron), an adjacent respiratory measurement technology with overlapping hospital and perioperative use cases.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Breathomix social profiles
Digital presenceBreathomix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Breathomix leadership team
Management profileNumber of profiles
Breathomix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Breathomix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Breathomix
What does Breathomix do?
Breathomix develops and delivers the BreathBase solution for point-of-care patient diagnosis and management. The solution is intended to bring breath-based diagnostic capability directly to the point-of-care rather than relying on centralized laboratory testing, enabling clinicians to assess and manage patients at the bedside or near-patient setting.
Is Breathomix a public or private company?
Breathomix is a private company. It is classified as unknown.
When was Breathomix founded?
Breathomix was founded in 2018. It employs 11 to 50 people.
Where is Breathomix based?
Breathomix is headquartered in Leiden, Netherlands, in the Europe region.
Who are Breathomix's main competitors?
Direct peers on record are Owlstone Medical, CAIRE Diagnostics (formerly Spirosure), Bedfont Scientific, ndd Medical Technologies, Vitalograph and MGC Diagnostics (now part of CAIRE). Bosch Healthcare Solutions (Vivatmo) is listed as a broad incumbent. Emerging players are AerNos and PulmOne Advanced Medical Devices. Respiratory Motion (ExSpiron) is listed as a regional player.
Does Breathomix have an API?
No public API is recorded for Breathomix.
What industry is Breathomix in?
Breathomix's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAGAH, Pulmonary Function Testing (PFT) & Spirometry Equipment, with a secondary code of HLAKANAC, Pulmonary Function Testing (PFT) & Respiratory Diagnostics. Its NAICS code is 62151 and its SIC code is 3841.